
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Lisa Egbuonu-Davis, MD, vice-president of global outcomes research and medical services for Pfizer, is determined to improve global access to necessary medicines.
almost 26 years ago
Neurology's Broader Promise: An Exclusive Interview with Christopher Reevealmost 26 years ago
The Top Ten Marketing Challenges in Neurologyalmost 26 years ago
A Right to Dream





